Proteostasis Therapeutics, Inc. Company Profile

16:00 EST 18th December 2018 | BioPortfolio

Proteostasis Therapeutics (PTI) is developing novel disease-modifying therapeutics that target the cellular pathways regulating protein folding, trafficking, and clearance. The Proteostasis Network (PN) is comprised of these interconnected cellular pathways and can become imbalanced by the cumulative effects of aging, disease, genetics and environmental factors. The Company is focused on improving outcomes for patients with neurodegenerative and orphan diseases with lead programs in cystic fibrosis and Parkinson’s disease. For more information, please visit

News Articles [701 Associated News Articles listed on BioPortfolio]

Genentech Licenses Non-CF Compound From Proteostasis in $100 Million-Plus Deal

Proteostasis Therapeutics, based in Boston, signed a worldwide, exclusive license deal with Genentech for rights to a possible small molecule modulator within the proteostasis network.

Proteostasis Therapeutics' Double and Triple-Combo CF Drugs Possible Threat to Vertex Dominance

Proteostasis Therapeutics announced positive preliminary data from its ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis (CF). Despite it being an early-stage trial and prelimin...

Proteostasis nets $69.8mm via FOPO

Proteostasis Therapeutics Inc. (cystic fibrosis therapies) netted $69.8mm through the follow-on offering of 11mm common shares at $6.75 each. The company will use the proceeds to fund critical path ac...

Proteostasis & Genentech Sign Licensing Deal

For rights to potential therapeutic small molecule modulators of an undisclosed target within the proteostasis network

Proteostasis Therapeutics: Sounding A Cautious Note

Proteostasis Therapeutics Delivered 400% Stock Returns

Proteostasis Therapeutics Surges On Cystic Fibrosis Data, Can The Run Continue?

Vertex CF Competitor Proteostasis Falters, Galapagos Up Next

Data released Wednesday afternoon looks to have eased a potential threat to Vertex Pharmaceuticals’ burgeoning cystic fibrosis franchise, though news from another challenger looms later this month. ...

PubMed Articles [515 Associated PubMed Articles listed on BioPortfolio]

Molecular Chaperones: From Proteostasis to Pathogenesis.

Maintaining protein homeostasis (proteostasis) is essential for a functional proteome. A wide range of extrinsic and intrinsic factors perturb proteostasis, causing protein misfolding, misassembly and...

Role of altered proteostasis network in chronic hypobaric hypoxia induced skeletal muscle atrophy.

High altitude associated hypobaric hypoxia is one of the cellular and environmental perturbation that alters proteostasis network and push the healthy cell towards loss of muscle mass. The present stu...

The Insulin/IGF signaling cascade modulates SUMOylation to regulate aging and proteostasis in .

Although aging-regulating pathways were discovered a few decades ago, it is not entirely clear how their activities are orchestrated, to govern lifespan and proteostasis at the organismal level. Here ...

Roles of the nucleotide exchange factor and chaperone Hsp110 in cellular proteostasis and diseases of protein misfolding.

Cellular protein homeostasis (proteostasis) is maintained by a broad network of proteins involved in synthesis, folding, triage, repair and degradation. Chief among these are molecular chaperones and ...

Hsp70 chaperone: a master player in protein homeostasis.

Protein homeostasis (proteostasis) is an essential pillar for correct cellular function. Impairments in proteostasis are encountered both in aging and in several human disease conditions. Molecular ch...

Clinical Trials [165 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia

At the time of biomarker-substantiated diagnosis for a given AD patient it remains unclear to what extent the disease will devastate cognitive abilities within the next years. This is not ...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1288 Associated Companies listed on BioPortfolio]

Proteostasis Therapeutics

Proteostasis Therapeutics is discovering “Proteostasis Regulators” (PRs), small molecule drugs that restore proper protein function to treat neurodegenerative, metabolic...

Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics (PTI) is developing novel disease-modifying therapeutics that target the cellular pathways regulating protein folding, trafficking, and clearance. The Pr...

Proteostasis Therapeutics and Elan Corporation

Proteostasis Therapeutics is developing “Proteostasis Regulators” (PRs), small molecule drugs that restore proper protein function or remove misfolded and aggregated pro...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Proteostasis Therapeutics, Inc." on BioPortfolio

We have published hundreds of Proteostasis Therapeutics, Inc. news stories on BioPortfolio along with dozens of Proteostasis Therapeutics, Inc. Clinical Trials and PubMed Articles about Proteostasis Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Proteostasis Therapeutics, Inc. Companies in our database. You can also find out about relevant Proteostasis Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Corporate Database Quicklinks

Searches Linking to this Company Record